2
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
10
Brain Neoplasms
8
Myelodysplastic Syndromes
7
Neoplasm Metastasis
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Glioblastoma
6
Recurrence
5
Lymphoma
5
Glioma
5
Sarcoma
4
Leukemia
4
Head and Neck Neoplasms
4
Colorectal Neoplasms
4
Astrocytoma
4
Ovarian Neoplasms
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Breast Neoplasms
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Neoplasms, Neuroepithelial
2
Nasopharyngeal Carcinoma
2
Mouth Neoplasms
2
Melanoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Interventions
Rituximab
112
Cyclophosphamide
103
fludarabine
61
Doxorubicin
33
Vincristine
31
Etoposide
31
Prednisone
30
Lenalidomide
24
ibrutinib
22
fludarabine phosphate
21
Immunotherapy, Adoptive
19
Bendamustine Hydrochloride
19
obinutuzumab
18
Cytarabine
18
pembrolizumab
16
Magnetic Resonance Spectroscopy
16
Bortezomib
14
Specimen Handling
13
Dexamethasone
13
polatuzumab vedotin
12
CT-P10
12
venetoclax
11
Gemcitabine
11
Carboplatin
11
pirtobrutinib
10
glofitamab
10
zanubrutinib
9
Nivolumab
9
Mycophenolic Acid
9
Melphalan
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Valproic Acid
×
Clear all
NCT02144623
2017-03-03
PREVAIL
Lund University Hospital
Phase EARLY_PHASE1
Completed
4 enrolled